Epix Seeks Partner To Market Vasovist
This article was originally published in The Pink Sheet Daily
Executive Summary
After a five-year ordeal, the firm gets FDA OK for the cardiovascular contrast agent.
You may also be interested in...
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
Epix Seeks New Vasovist Partner After Bayer Backs Out
Focus on competing Magnevist could have prompted Bayer Schering’s decision.